ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction
暂无分享,去创建一个
D. Neuberg | M. Mihm | F. Hodi | G. Dranoff | J. Ritz | R. Salgia | R. Soiffer | Jihong Yang | E. Alyea | J. Schmollinger | T. Lynch
[1] H. Ikeda,et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] H. Ditzel,et al. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] P. Kantoff,et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Rosenberg,et al. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] E. Jaffee,et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.
[6] Mark M. Davis,et al. Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.
[7] D. Jäger,et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[8] V. Schoonderwoert,et al. Inhibition of the vacuolar H+-ATPase perturbs the transport, sorting, processing and release of regulated secretory proteins. , 2000, European journal of biochemistry.
[9] D. Neuberg,et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[10] M. Mihm,et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. , 2000, Cancer research.
[11] D. Jäger,et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] C. Brown,et al. Determination of X-chromosome inactivation status using X-linked expressed polymorphisms identified by database searching. , 2000, Genomics.
[13] Jonathan J. Lewis,et al. Coupling and Uncoupling of Tumor Immunity and Autoimmunity , 1999, The Journal of experimental medicine.
[14] D. Jäger,et al. Antigens recognized by autologous antibody in patients with renal‐cell carcinoma , 1999, International journal of cancer.
[15] E. Gilboa. The makings of a tumor rejection antigen. , 1999, Immunity.
[16] V. Schoonderwoert,et al. Biosynthesis of the vacuolar H+-ATPase accessory subunit Ac45 in Xenopus pituitary. , 1999, European journal of biochemistry.
[17] T. Hercend,et al. A MAGE‐6‐encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion , 1999, European journal of immunology.
[18] T. Hercend,et al. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation , 1999, European journal of immunology.
[19] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[20] D. Neuberg,et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Burbach,et al. Intracellular trafficking of the vacuolar H+-ATPase accessory subunit Ac45. , 1998, Journal of cell science.
[22] Yao-Tseng Chen,et al. Characterization of human colon cancer antigens recognized by autologous antibodies , 1998, International journal of cancer.
[23] D. Neuberg,et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. , 1998, Blood.
[24] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[25] Wen-Hwa Lee,et al. Identification of a Novel Cytoplasmic Protein That Specifically Binds to Nuclear Localization Signal Motifs* , 1998, The Journal of Biological Chemistry.
[26] A. Houghton,et al. Fc receptors are required in passive and active immunity to melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Houghton,et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Laslop,et al. Chromaffin granule membrane glycoprotein IV is identical with Ac45, a membrane-integral subunit of the granule's H+-ATPase , 1996, Neuroscience Letters.
[29] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[30] E. Jansen,et al. Molecular probing of the secretory pathway in peptide hormone-producing cells. , 1995, Journal of cell science.
[31] F. Supek,et al. A novel accessory subunit for vacuolar H(+)-ATPase from chromaffin granules. , 1994, The Journal of biological chemistry.
[32] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Houghton. Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.
[34] E. Jaffee,et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.
[35] C. Figdor,et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[36] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[37] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.